Pharmacokinetics and tissue distribution studies of orally administered nanoparticles encapsulated ethionamide used as potential drug delivery system in management of multi-drug resistant tuberculosis

References

• Auclair, B., Nix, D.E., Adam, R.D., James, G.T., Peloquin, C.A. (2001). Pharmacokinetics of ethionamide administered under fasting conditions or with orange juice, food, or antacids. Antimicrob Agents Chemother. 45:810–4.
   PubMed Web of Science ®Google Scholar
• Bass, J.B., Jr., Farer, L.S., Hopewell, P.C., O’Brien, R., Jacobs, R.F., Ruben, F., Snider, D.E., Jr., Thornton, G. (1994). Treatment of tuberculosis and tuberculosis infection in adults and children. American thoracic society and the centers for disease control and prevention. Am J Crit Care Med. 149:1359–74.
   Web of Science ®Google Scholar
• Craig, W.A. (1998). Pharmacokinetic/pharmacodynamic parameters: rationale for antibacterial dosing of mice and men. Clin Infect Dis. 26:1–12.
   PubMed Web of Science ®Google Scholar
• Desai, M.P., Labhasetwar, V., Amidon, G.L., Levy, R.J. (1996). Gastrointestinal uptake of biodegradable microparticles: effect of particle size. Pharm Res. 13:1838–45.
   PubMed Web of Science ®Google Scholar
• Drummond, D.C., Noble, C.O., Guo, Z., Hayes, M.E., Park, J.W., Ou, C.-J., Tseng, Y.-L., Hong, K., Kirpotin, D.B. (2009). Improved pharmacokinetics and efficacy of a highly stable nanoliposomal vinorelbine. J Pharm Exp Ther. 328:321–30.
   PubMed Web of Science ®Google Scholar
• Florence, A.T. (1997). The oral absorption of micro and nanoparticulates: neither exceptional nor unusual. Pharm Res. 14:259–65.
   PubMed Web of Science ®Google Scholar
• Florence, A.T. (2005). Nanoparticle uptake by the oral route: fulfilling its potential? Dr Discov Today: Technologies. 2:75–81.
   Google Scholar
• Frimodt-Moller, N. (2002). How predictive is PK/PD for antibacterial agents. Int J antimicrob agents. 19:333–9.
   PubMed Web of Science ®Google Scholar
• Gronroos, J.A., Toivanen, A. (1964). Blood ethionamide levels after administration of enteric coated and uncoated tablets. Curr Ther Res. 6:105–14.
   PubMed Web of Science ®Google Scholar
• Hariharan, S., Bhardwaj, V., Bala, I., Sitterberg, J., Bakowsky, U., Ravi Kumar, M.N.V. (2006). Design of estradiol loaded PLGA nanoparticulate formulations: a potential oral delivery system for hormone therapy. Pharm Res. 23:184–95.
   PubMed Web of Science ®Google Scholar
• Italia, J.L., Bhatt, D.K., Bhardwaj, V., Tikoo, K., Kumar, M.N. (2007). PLGA nanoparticles for oral delivery of cyclosporine: nephrotoxicity and pharmacokinetic studies in comparison to Sandimmune Neoral. J Contr Rel. 119:197–206.
   PubMed Web of Science ®Google Scholar
• James, G.T., McCarthy, E. (1991). Improved high performance liquid chromatographic assay for the determination of ethionamide in serum. J Chromatography. 563:472–5.
   PubMed Web of Science ®Google Scholar
• Kalaria, D.R., Sharma, G., Beniwal, V., Ravi Kumar, M.N.V. (2009). Design of biodegradable nanoparticles for oral delivery of doxorubicin: in vivo pharmacokinetics and toxicity studies in rats. Pharmaceutical research. 26:492–501.
   PubMed Web of Science ®Google Scholar
• Lamprecht, A., Ubrich, N., Yamamoto, H., Schafer, U., Takeuchi, H., Maincent, P., Kawashima, Y., Lehr, C.M. (2001). Biodegradable nanoparticles for targeted drug delivery in treatment of inflammatory bowel disease. J Pharmacol Exp Ther. 299:775–81.
   PubMed Web of Science ®Google Scholar
• Matuszewski, B.K., Constanzer, M.L., Chavez-Eng, C.M. (2003). Strategies for the assessment of matrix effect in quantitative bioanalytical methods based on HPLC-MS/MS. Anal Chem. 75:3019–30.
   PubMed Web of Science ®Google Scholar
• Muller, R.H., Jacobs, C., Kayser, O. (2001). Nanosuspensions as particulate drug formulations in therapy rationale for development and what we can expect for the future. Adv Drug Deliver Rev. 47:3–19.
   PubMed Web of Science ®Google Scholar
• Nahar, M., Mishra, D., Dubey, V., Jain, N.K. (2008). Development, characterization, and toxicity evaluation of amphotericin B-loaded gelatin nanoparticles. Nanomedicine. 4:252–61.
   PubMed Web of Science ®Google Scholar
• Norris, D.A., Puri, N., Sinko, P.J. (1998). The effect of physical barriers and properties on the oral absorption of particulates. Adv Drug Deliver Rev. 34:135–54.
   PubMed Web of Science ®Google Scholar
• Pandey, R., Sharma, A., Ahmad, Z., Sharma, S., Khuller, G.K., Prasad, B. (2003a). Poly (DL-lactide-co-glycolide) nanoparticle-based inhalable sustained drug delivery system for experimental tuberculosis. J Antimicrob Chemother. 52:981–6.
   PubMed Web of Science ®Google Scholar
• Pandey, R., Zahoor, A., Sharma, S., Khuller, G.K. (2003b). Nanoparticle encapsulated antitubercular drugs as apotential oral drug delivery system against murine tuberculosis. Tuberculosis. 83:373–8.
   PubMed Web of Science ®Google Scholar
• Radwan, M.A., Zaghloul, I.Y., Aly, Z.H. (1999). In vivo performance of parenteral theophylline- loaded polyisobutylcynoacrylate nanoparticles in rats. Eur J Pharm Sci. 8:95–8.
   PubMed Web of Science ®Google Scholar
• Rojas, J., Pinto-Alphandary, H., Leo, E., Pecquet, S., Couvreur, P., Fattal, E. (1999). Optimization of the encapsulation and release of beta-lactoglobulin entrapped poly(DL-lactide-co-glycolide) microspheres. Int J Pharm. 183:67–71.
   PubMed Web of Science ®Google Scholar
• Schmidt, S., Barbour, A., Sahre, M., Rand, K.H., Derendorf, H. (2008). PK/PD: new insights for antibacterial and antiviral applications. Curr Opin Pharmacol. 8:549–56.
   PubMed Web of Science ®Google Scholar
• Veera Reddy, P.R., Vobalaboina, V., Ali, N. (2009). Antileishmanial activity, pharmacokinetics and tissue distribution studies of mannose-grafted amphotericin B lipid nanosphere. J Drug target. 17:140–7.
   PubMed Web of Science ®Google Scholar
• www.fda.gov/ CDER/ Guidance for industry/ ICH Q2B document: Validation of analytical procedures: Methodology/ Nov. 1996/ Accessed on: 10/07/2008.
   Google Scholar
• Weiling, H., Horn, S.W., Hussain, M.D. (2007). Improved bioavailability of orally administered mifepristone from PLGA nanoparticles. Int J Pharm. 34:173–8.
   Google Scholar
• Weinstein, H.J., Hallett, W.Y., Sarauw, A.S. (1962). The absorption and toxicity of ethionamide. Am Rev Respir Dis. 86:576–8.
   PubMed Web of Science ®Google Scholar
• Zhu, M., Namdar, R., Stambaugh, J.J., Starke, J.R., Bulpitt, A.E., Berning, S.E., Peloquin, C.A. (2002). Population pharmacokinetics of ethionamide in patients with tuberculosis. Tuberculosis. 82:91–6.
   PubMed Web of Science ®Google Scholar